India’s healthcare and pharmaceutical communications landscape is at a critical
inflection point. As scientific innovation accelerates, the industry is moving beyond
conventional messaging towards engagement models that are medically robust,
experience-led, compliant, and demonstrably measurable. Yet, a longstanding gap
persists – between agencies that deeply understand science and those that excel at
large-scale experiential execution.
Addressing this unmet need, Havas Life Mumbai (the healthcare agency of Havas
India) and Shobiz (Havas India’s experiential agency) have come together to deliver
fully integrated, end-to-end experiential solutions for healthcare and pharma brands in India.
The collaboration brings together Havas Life Mumbai’s deep expertise in health and
medical communications with Shobiz’s proven strength in innovation-led experiential design and execution, creating a single, unified partner capable of bridging strategy and execution seamlessly. Together, the two agencies under Havas India aim to redefine how healthcare brands engage healthcare professionals (HCPs), patients, and caregivers, through experiences that are scientifically credible, creatively compelling, fully compliant, and outcome driven. The partnership will enable brands to leverage next-generation engagement solutions, including immersive VR, AR, MR simulations, AI-powered interactive tools, and data-driven engagement platforms, setting new benchmarks for impact and effectiveness across the industry.
Charles Houdoux, Global Chief Client Officer Havas Health, CEO APAC-LATAM
said, “By uniting the scientific rigor and healthcare leadership of Havas Life Mumbai, with the transformative power of experience design from Shobiz, we are redefining how the industry engages with healthcare professionals. This collaboration is not simply about communication or events — it is about building a new paradigm where knowledge, emotion, and experience converge to accelerate the understanding and adoption of innovation. Together, we are shaping a more connected, more immersive, and ultimately more impactful future for healthcare engagement — one that drives better decisions, deeper trust, and improved patient outcomes.”
Rana Barua, Group CEO, Havas India, SEA & North Asia (Japan and South
Korea) said, “The collaboration between Havas Life Mumbai and Shobiz brings
together two extraordinary powerhouses, one rooted in deep medical intelligence,
the other in experiential innovation at scale. This partnership enables us to move
beyond traditional engagement and create truly differentiated, more desirable
experiences for the world of health & wellness. This is the future of experiential
healthcare in India, and we are proud to be leading it.”
Commenting on the partnership, Dorelle Kulkarni, Managing Director, Havas Life
Mumbai said, “Healthcare brands today need far more than communication—they
need experiences that simplify complex science, inspire action, and build long-term
trust. Our partnership with Shobiz brings together deep medical intelligence with
world-class experiential capability, allowing us to create transformative, insight-led
engagements that are impactful and measurable. Together, we are setting a new
standard for health experiences in India.”
Sameer Tobaccowala, CEO, Shobiz said, “The future of healthcare engagement
lies at the intersection of scientific credibility and immersive, thoughtfully curated
experiences. By combining Shobiz’s legacy of delivering large-scale, technology-
driven experiential solutions with Havas Life Mumbai’s deep understanding of the
healthcare ecosystem, we are uniquely positioned to offer clients truly integrated and compliant engagement platforms that deliver tangible business outcomes and move the industry forward.”
With this partnership, Havas Life Mumbai and Shobiz aim to not only elevate
experiential engagement for healthcare and pharma brands but also shape the future of how medical science is communicated, experienced, and acted upon in India.
Read also: IPL 2026: When the Game Pauses, the Marketing Never Does
Disclaimer: Information mentioned here has not been verified or endorsed by Agency Reporter and is in accordance with the press release shared by the company or their appointed representatives
